Last reviewed · How we verify
Evaluation of Meningococcal C Vaccine Programmes in Canadian (BC, NS, Alta.) Children During Peak Years of Risk (0-<5 Years of Age)
The purpose of the study is to see which of the three current provincial Meningococcal C Conjugate vaccine schedules in Canada provide the longest lasting protection against Meningococcal C disease and to see if a booster vaccination is needed.
Details
| Lead sponsor | University of British Columbia |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 452 |
| Start date | 2009-07 |
| Completion | 2015-06 |
Conditions
- Meningococcal Sero-type C Infection
Interventions
- NeisVac C vaccine (12mth)
Primary outcomes
- To evaluate the longest lasting protection against Meningococcal C disease and to see if a booster vaccination is needed. — 4 years
Countries
Canada